ARTICLE SUMMARY:
Market Pathways' editors highlight the major medtech policy issues and developments they'll be tracking in 2025 and count down the top 10 global policy documents of 2024; Former CMS medical director Lee Fleisher shares his views on the major reimbursement challenges currently facing product companies. In Consultants Corner, MCRA executives offer practical guidance on diversifying device trials and implementing diversity action plans.
